Anti-Cbl proto-oncogene C antibodies are used in the immunodetection of the protein encoded by the CBLC gene. In humans, the canonical protein has a reported length of 474 amino acid residues and a mass of 52.5 kDa. Alternative splicing is reported to yield 2 different isoforms for this protein. It is ubiquitously expressed across many tissue types. It is known to act as a E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Post-translational modifications have been described, including ubiquitination and phosphorylation. Other names for this target antigen include CBL-SL, RNF57, E3 ubiquitin-protein ligase CBL-C, Cas-Br-M (murine) ecotropic retroviral transforming sequence c, and CBL-3.